MoonLake Immunotherapeutics (MLTX) Stock

MoonLake Immunotherapeutics (MLTX) is a Healthcare stock trading at $19.21 (as of 2026-06-18), with a market capitalization of $1.41B and a trailing P/E of -5.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing therapeutic candidates, including Sonelokimab, an investigational nanobody therapy for inflammation. It is conducting Phase II trials in conditions such as hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis.

Valuation — source: SEC EDGAR (first-party)
Price	$19.21
Market Cap	$1.41B
P/E Ratio	-5.0
EV / EBITDA	-4.6
Price / Book	5.57
DCF Value (model)	$-47.73
DCF Upside vs Price	-348.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$27691.00
Net Margin	-16404.8%
Return on Equity	-101.2%
Debt / Equity	0.39
Current Ratio	8.60

Valuation vs Sector & Industry
Stock P/E	-5.0
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-123.6%
vs Industry	-128.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BVF INC/IL ($298.26M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jorge Santos da Silva
Employees	100
Country	CH
IPO Date	2020-10-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.